Skip to main content
< Back to news

EIT Health selects Droplite, Ninevah and Oxolife for Headstart program

Droplite, Ninevah Therapeutics and Oxolife, presents at the Barcelona Science Park, are three of the 16 Spanish startups that will participate in Headstart, the program of the European Institute of Innovation and Technology in Health (EIT Health) that offers support and financing of up to 50,000 € because emerging companies develop their innovations within a unique ecosystem, which gives them access to financing, experts, contacts and knowledge.


Droplite Technologies, Ninevah Therapeutics and Oxolife are three of the 16 Spanish startups that are part of the total of 89 companies across Europe chosen by EIT Healt to accelerate their projects within the Headstart program.

Droplite Technologies introduces a novel in-vitro smart diagnostics device, that delivers accurate test results in 10 minutes for the detection and quantification of specific diseases and health conditions. The innovation is based on an immunoassay biochemical testing technique.

Ninevah Therapeutics brings forward a first-in-class gene therapy able to treat all patients with genetic Nephrotic Syndrome (NS).

Oxolife is developing a first-in-class pharmacological product, OXO-001, to increase embryo implantation to fulfil an unmet need in female fertility treatment. Through a direct effect on the endometrium, OXO-001 could allow pregnancy many infertile women who currently lack optimal fertility treatment.

EIT Health Headstart programme accelerates the market launch of selected healthcare start-ups through grants as well as support with networking and developing a project plan. Headstart awards companies up to €50,000 to support start-ups in realising next steps for market launch; verify the need/benefit of the product/service; increase the possibility of attracting private investment. This year, Headstart is supplemented by two special programmes, COVID-19 and NAM.

“We are thrilled to support the start-ups selected this year through the Headstart programme. Each one presented an incredibly strong proposition for the development of solutions to improve the lives of European patients and citizens in areas of high unmet need. I am also proud to see the speed at which our applicants were able to respond to our call for COVID-19 solutions – it is truly a demonstration of the agility and astuteness that lies within the start-up community we have here in Europe.” said Dr. Kurt Höller, Director of Business Creation at EIT Health.

► For further information: EIT Health Spain website [+]